Control of fetal hemoglobin: new insights emerging from genomics and clinical implications
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Increased levels of fetal hemoglobin (HbF, alpha(2)gamma(2)) are of no consequence in healthy adults, but confer major clinical benefits in patients with sickle cell anemia (SCA) and beta thalassemia, diseases that represent major public health problems. Inter-individual HbF variation is largely genetically controlled, with one extreme caused by mutations involving the beta globin gene (HBB) complex, historically referred to as pancellular hereditary persistence of fetal hemoglobin (HPFH). These Mendelian forms of HPFH are rare and do not explain the common form of heterocellular HPFH which represents the upper tail of normal HbF variation, and is clearly inherited as a quantitative genetic trait. Genetic studies have identified three major quantitative trait loci (QTLs) (Xmn1-HBG2, HBS1L-MYB intergenic region on chromosome 6q23, and BCL11A on chromosome 2p16) that account for 20-50% of the common variation in HbF levels in patients with SCA and beta thalassemia, and in healthy adults. Two of the major QTLs include oncogenes, emphasizing the importance of cell proliferation and differentiation as an important contribution to the HbF phenotype. The review traces the story of HbF quantitative genetics that uncannily mirrors the changing focus in genetic methodology, from candidate genes through positional cloning, to genome-wide association, that have expedited the dissection of the genetic architecture underlying HbF variability. These genetic results have already provided remarkable insights into molecular mechanisms that underlie the hemoglobin 'switch'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
The American Journal of Human Genetics
S., J. (1950) · Population (French Edition) · doi:10.2307/1523704 · Cited by 5,028
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891 · cited 1×
“Identifying the common alleles will require large population samples for additional screening studies and even larger samples for replication, and possibly denser maps (62).”
BackgroundThe Wellcome Trust Case Control Consortium, U.K.
Mossman, K. (2008) · Scientific American · doi:10.1038/scientificamerican0108-42a · Cited by 2,684
Genetic Mapping in Human Disease
Altshuler, D., Daly, M. J., & Lander, E. S. (2008) · Science · doi:10.1126/science.1156409 · Cited by 1,452
Common variants at 30 loci contribute to polygenic dyslipidemia
Kathiresan, S., Willer, C. J., Peloso, G. M., Demissie, S., Musunuru, K., Schadt, E. E., Kaplan, L., Bennett, D., Li, Y., Tanaka, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.291 · Cited by 1,364
Self-citationCommon and rare variants in multifactorial susceptibility to common diseases
Bodmer, W., & Bonilla, C. (2008) · Nature Genetics · doi:10.1038/ng.f.136 · Cited by 1,131
Common Genetic Variation and Human Traits
Goldstein, D. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0806284 · Cited by 920 · cited 1×
“Identification of rare alleles will also require next-generation DNA sequencing technologies and statistical analysis methods that enable genomewide sequence analysis in large samples (63).”
MethodHuman Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11A
Sankaran, V. G., Menne, T. F., Xu, J., Akie, T. E., Lettre, G., Van Handel, B., Mikkola, H. K. A., Hirschhorn, J. N., Cantor, A. B., & Orkin, S. H. (2008) · Science · doi:10.1126/science.1165409 · Cited by 919
A HapMap harvest of insights into the genetics of common disease
Manolio, T. A., Brooks, L. D., & Collins, F. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34772 · Cited by 889
Cited by
Items 101–200 of 288
The Sub-Phenotypes of Sickle Cell Disease in Kuwait
Adekile, A. D., Al-Sherida, S., Marouf, R., Mustafa, N. Y., & Thomas, D. (2019) · Hemoglobin · doi:10.1080/03630269.2019.1610427 · Cited by 21
Gravia, A., Chondrou, V., Κολλιοπούλου, Α., Kourakli, A., John, A., Symeonidis, A. S., Ali, B. R., Sgourou, A., Papachatzopoulou, A., Κάτσιλα, Θ., et al. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0076 · Cited by 21
Cyrus, C., Vatte, C., Borgio, J. F., Al‐Rubaish, A. M., Chathoth, S., Naserullah, Z. A., Al‐Jarrash, S., Sulaiman, A., Qutub, H. O., Alsaleem, H., et al. (2017) · BioMed Research International · doi:10.1155/2017/1972429 · Cited by 19
“This is consistent with previous reports from European, Chinese and African β-thalassemia intermedia and SCD patients [9, 13, 20, 22, 23, 25, 26, 28].”
BackgroundResultYang, K., Wu, Y., Ma, Y., Xiao, J., Zhou, Y., & Yin, X. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102442 · Cited by 18
El-Ghamrawy, M., Yassa, M. E., Tousson, A. M. S., Elhady, M. A., Mikhaeil, E., Mohamed, N. B., & Khorshied, M. M. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04187-z · Cited by 18
Neishabury, M., Zamani, S., Azarkeivan, A., Abedini, S. S., Darvish, H., Zamani, F., & Najmabadi, H. (2011) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2011.10.001 · Cited by 18
Genetics of fetal hemoglobin in tribal Indian patients with sickle cell anemia
Bhanushali, A. A., Patra, P. K., Pradhan, S., Khanka, S. S., Singh, S., & Das, B. R. (2015) · Translational research · doi:10.1016/j.trsl.2015.01.002 · Cited by 17
Uchida, N., Ferrara, F., Drysdale, C. M., Yapundich, M., Gamer, J., Nassehi, T., DiNicola, J., Shibata, Y., Wielgosz, M. M., Kim, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0411 · Cited by 17
Xmn1-158 γGVariant in B-Thalassemia Intermediate Patients in South-East of Iran.
Miri‐Moghaddam, E., Bahrami, S., Naderi, M., Bazı, A., & Karimipoor, M. (2017) · PubMed Central · Cited by 17
Breveglieri, G., Bianchi, N., Cosenza, L. C., Gamberini, M. R., Chiavilli, F., Zuccato, C., Montagner, G., Borgatti, M., Lampronti, I., Finotti, A., et al. (2017) · BMC Medical Genetics · doi:10.1186/s12881-017-0450-3 · Cited by 17
Genetic Modifiers in β-Thalassemia Intermedia: A Study on 102 Iraqi Arab Patients
Al-Allawi, N. A. S., Puehringer, H., Raheem, R. A., & Oberkanins, C. (2015) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2014.0310 · Cited by 17
“The three major quantitative trait loci (QTLs) are the Xmn I -158 C > T promoter polymorphism in the HBG2 gene, the BCL11A gene located on chromosome 2, and the HBS1L-MYB intergenic region on chromosome 6 (Thein et al. , 2009; Taher et al. , 2013).”
Functional categorization of gene regulatory variants that cause Mendelian conditions
Cheng, Y.-H. H., Bohaczuk, S. C., & Stergachis, A. B. (2024) · Human Genetics · doi:10.1007/s00439-023-02639-w · Cited by 17
“…sickle hemoglobin (HbS) and can compensate for deficient HbA as seen in beta-thalassemia, these HPFH variants can attenuate the phenotype of sickle cell disease and beta-thalassemia (Jackson et al. 1961; Cappellini et al. 1981; Labie et al. 1985; Weatherall 2001; Thein 2008; Thein et al. 2009).”
BackgroundLim, W. F., Muniandi, L., George, E., Sathar, J., Teh, L. K., Gan, G. G., & Lai, M. I. (2011) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2011.10.002 · Cited by 16
Physiological and Aberrant γ-Globin Transcription During Development
Barbarani, G., Łabędź, A., Stucchi, S., Abbiati, A., & Ronchi, A. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.640060 · Cited by 17
Banan, M., Bayat, H., Namdar‐Aligoodarzi, P., Azarkeivan, A., Kamali, K., Daneshmand, P., Zaker-Kandjani, B., & Najmabadi, H. (2013) · Hemoglobin · doi:10.3109/03630269.2013.805418 · Cited by 16
“0% of the Hb F variance in β-thal patients (28).”
BackgroundGenetic control of erythropoiesis
Tumburu, L., & Thein, S. L. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000333 · Cited by 16
Self-citationAl-Allawi, N. A. S., Qadir, S. M. A., Puehringer, H., Chui, D. H. K., Farrell, J. J., & Oberkanins, C. (2018) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12927 · Cited by 16
Nicolau, M., Vargas, S., Silva, M., Coelho, A., Ferreira, E., Mendonça, J., Vieira, L., Kjöllerström, P., Maia, R., Silva, R., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03783-y · Cited by 16
Qian, X.-H., Chen, J., ZHAO, D., GUO, L., & Qian, X. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1338 · Cited by 16
“Significant progress has been made over the past decade (42-45).”
BackgroundNeishabury, M., Zamani, F., Keyhani, E., Azarkeivan, A., Abedini, S. S., Eslami, M. S., Kakroodi, S. T., Vesiehsari, M. J., & Najmabadi, H. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.02.007 · Cited by 16
“To further examine this hypothesis, the influence of the 5′HS4-LCR genotypic background on phenotype modifying effect of 2 BCL11A SNPs within intron 2 of this gene, (rs11886868 and rs766432) [8,11], was examined in 100 Iranian patients with different 5′HS4-LCR backgrounds in the homozygous state and in 122 normal indi…”
BackgroundAimola, I. A., Inuwa, H. M., Nok, A. J., & Mamman, A. I. (2014) · Cell Biochemistry and Function · doi:10.1002/cbf.3024 · Cited by 16
Transcriptional Repressors of Fetal Globin Genes as Novel Therapeutic Targets in Beta-Thalassemia
Martino, M. D., Sessa, R., Storino, M. R., Giuliano, M., Trombetti, S., Catapano, R., Bianco, A. L., Izzo, P., & Grosso, M. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.90762 · Cited by 15
Finotti, A., Gasparello, J., Breveglieri, G., Cosenza, L. C., Montagner, G., Bresciani, A., Altamura, S., Bianchi, N., Martini, E., Gallerani, E., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.08.011 · Cited by 15
Tribal distribution of haemoglobinopathies in a Sudanese patient population
Elderdery, A. Y., Mohamed, B. A., Cooper, A., Knight, G., & Mills, J. J. (2011) · Journal of Medical Laboratory and Diagnosis · doi:10.5897/jmld.9000013 · Cited by 15
A phase 2 study of HQK ‐1001, an oral fetal haemoglobin inducer, in β‐thalassaemia intermedia
Inati, A. C., Kahale, M., Perrine, S. P., Chui, D. H. K., Taher, A. T., Koussa, S., Nasr, T. A., Abbas, H. A., & Ghalie, R. (2013) · British Journal of Haematology · doi:10.1111/bjh.12635 · Cited by 14
“Table I presents each subject’s thalassaemia mutations and polymorphisms for three quantitative trait loci (QTL) that were shown to strongly influence baseline HbF lev- els (Thein et al, 2009).”
BackgroundAdelvand, P., Hamid, M., & Sardari, S. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1406795 · Cited by 14
“Three major QTLs have been shown to control about 20–50% of Hb F variations in healthy human adults and in patients with hemoglobinopathies including β-thalassemia [42] and SCD patients.”
BackgroundGenetic Factors Modifying Sickle Cell Disease Severity
Gardner, K., & Thein, S. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-06713-1_15 · Cited by 14
Self-citationKerdpoo, S., Limweeraprajak, E., & Tatu, T. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1516-z · Cited by 14
“, b-hemoglobinopathies [2, 33].”
BackgroundGenotypic Diversity among Angolan Children with Sickle Cell Anemia
Delgadinho, M., Ginete, C., Santos, B., Miranda, A., & Brito, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105417 · Cited by 13
“To date, SNPs within the intron 2 of BCL11A appear to have the most impact on HbF expression [16].”
BackgroundResultPostnatal gestational age estimation via newborn screening analysis: application and potential
Wilson, L. A., Murphy, M. S. Q., Ducharme, R., Denize, K. M., Jadavji, N. M., Potter, B. K., Little, J., Chakraborty, P. K., Hawken, S., & Wilson, K. R. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1654863 · Cited by 13
“Because of the known relationship between the ratio of fetal-to-adult hemoglobin (Hb) levels and GA [25], and the relative ease of measuring Hb levels compared to other newborn screening analytes (measured by HPLC versus MS/MS), we investigated the ratio of fetal-to-adult Hb as a potential new predictor of GA in our o…”
BackgroundNovel and innovative approaches for treatment of β-thalassemia
Soni, S. (2017) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2017.11.153 · Cited by 13
Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia
Eridani, S., & Mosca (2011) · Journal of Blood Medicine · doi:10.2147/jbm.s14942 · Cited by 13
A Review of Gene Therapies for Hemoglobinopathies
Jones-Wonni, B., Kelkar, A. H., & Achebe, M. (2024) · Hemoglobin · doi:10.1080/03630269.2024.2369534 · Cited by 12
“In patients with co-inheritance of hereditary persistence of HbF, the severity of β-hemoglobinopathies is diminished [49, 50].”
Hegde, M., & Crowley, M. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812537-3.00004-4 · Cited by 12
Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction.
Habibi, H., Atashi, A., Abroun, S., & Noruzinia, M. (2019) · PubMed Central · doi:10.22074/cellj.2019.5589 · Cited by 12
“Typically, these patients have no symptoms at birth and clinical manifestations appear with HbF (α2γ2) switching to HbA (α2β2) six months after birth (8-10).”
BackgroundKarimi, M., Zarei, T., Haghpanah, S., Moghadam, M., Ebrahimi, A., Rezaei, N., Heidari, G., Vazin, A., Khavari, M., & Miri, H. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000779 · Cited by 12
Thalassemia — From Genotype to Phenotype
El‐Kamah, G. Y., & Amr, K. S. (2015) · InTech eBooks · doi:10.5772/61433 · Cited by 11
“As the phenotype correlates with α-globin chain deficiency and improved α/non-α chain imbalance, an increased residual level of HbF in adult life compensates the decreased β- globin chain, hence a major determinant of disease severity [45,46].”
BackgroundBohara, V., Raut, L. S., Badarkhe, G., Roy, S. S., & Chaudhuri, U. (2012) · Hemoglobin · doi:10.3109/03630269.2012.751395 · Cited by 11
“0% of the common variation in Hb F levels in patients with sickle cell anemia and β-thal (8), the others being Xp22.”
BackgroundTo respond or not to respond to hydroxyurea in thalassemia: a matter of stress adaptation?
Ronchi, A. E., & Ottolenghi, S. (2013) · Haematologica · doi:10.3324/haematol.2013.084392 · Cited by 11
“High HbF is protective against sickling and vaso-occlusive complications in SCA, and high levels of gamma-globin (the non-alpha globin component of HbF) compensate for beta-globin deficiency in BT, reducing the alpha/non-alpha-globin imbalance.(1)”
BackgroundZaker-Kandjani, B., Namdar‐Aligoodarzi, P., Azarkeivan, A., Najmabadi, H., & Banan, M. (2015) · Hemoglobin · doi:10.3109/03630269.2014.991023 · Cited by 10
“These genotypes may partially account for the low Hb F levels in this patient (23).”
BackgroundPrevalence of Xmnl Gγ polymorphism in Egyptian patients with β-thalassemia major
Tantawy, A. A. G., Andrawes, N. G., Ismaeil, A. A.-E., Kamel, S. A., & Emam, W. (2012) · Annals of Saudi Medicine · doi:10.5144/0256-4947.2012.487 · Cited by 10
Control of globin gene expression by Kruppel-like factors
Grech, L., & Borg, J. (2014) · OAR@UM (University of Malta) · doi:10.7423/xjenza.2014.1.10 · Cited by 10
“In the majority of adults, Hb F consists of less than 2% to total Hb, but there is considerable variation (Thein et al., 2009).”
BackgroundStephanou, C., Menzel, S., Philipsen, S., & Kountouris, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111408 · Cited by 9
“In healthy individuals, HbF continues to be synthesized beyond early childhood at residual levels ( 1% of total Hb) with considerable variation between individuals [8].”
BackgroundSelf-citationHabara, A. H. (2025) · Cells · doi:10.3390/cells14040312 · Cited by 9
“HbF levels are strongly associated with the SNPs rs766432, rs11886868, and rs4671393, which are situated within intron 2 of the BCL11A gene [70] and are likely to be within the sequence of some of the circRNAs expressed from BCL11A , namely hsa-BCL11A_0011 and hsa-BCL11A_0038, according to…”
Molecular Diagnostics of ß-Thalassemia
Plaseska‐Karanfilska, D., Atanasovska, B., Bozhinovski, G., Chakalova, L., Kocheva, S. A., & Каранфилски, О. (2012) · Balkan Journal of Medical Genetics · doi:10.2478/v10034-012-0021-z · Cited by 9
“The severity of the clinical symptoms depends on the molecular consequences of the genetic abnormality or combination thereof and is modulated by other genetic and environmental factors [2,5,6].”
BackgroundHemoglobin Lepore EF Bart’s disease: a molecular, hematological, and diagnostic aspects
Chaibunruang, A., Fucharoen, G., Jetsrisuparb, A., & Fucharoen, S. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1173-8 · Cited by 9
Prasing, W., Mekki, C., Traisathit, P., Pissard, S., & Pornprasert, S. (2017) · Walailak Journal of Science and Technology (WJST) · doi:10.48048/wjst.2018.3151 · Cited by 9
Shen, Y., Bassett, M., Gurumurthy, A., Nar, R., Knudson, I. J., Guy, C. R., Perez, A., Mellen, R. W., Ikeda, M., Hossain, M. A., et al. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00197-18 · Cited by 9
“Furthermore, mutations in DNA sequences regulating expression of the transcription repressor B cell chronic lymphocytic leukemia (CLL)/lymphoma 11A (BCL11A) have been linked to elevated expression of fetal hemoglobin (16, 17).”
Backgroundda Silva, J. P. M. D. O., Brugnerotto, A. F., Romanello, K. S., Teixeira, K. K. L., Lanaro, C., Duarte, A. S. S., Costa, G. G. L., Araújo, A. D. S., Bezerra, M., Domingos, I. F., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16062 · Cited by 9
“The majority of these mutations comprise single nucleotide substitutions, deletions or insertions leading to frame shift alteration (Thein et al, 2009; Cao & Galanello, 2010).”
BackgroundRopero, P., Peral, M., Sánchez-Martínez, L. J., Rochas, S., Gómez-Álvarez, M., Nieto, J. M., González, F. A., Villegas, A., & Benavente, C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1347026 · Cited by 8
Hossain, M. A., Shen, Y., Knudson, I. J., Thakur, S., Stees, J. R., Qiu, Y., Pace, B. S., Peterson, K. R., & Bungert, J. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.85 · Cited by 9
Primary Prophylaxis in Sickle Cell Disease: Is It Feasible? Is It Effective?
Thompson, A. A. (2011) · Hematology · doi:10.1182/asheducation-2011.1.434 · Cited by 8
Natiq, A., Lysy, P. A., Gillemans, N., Schaap, R., Sefiani, A., Amzazi, S., Elalaoui, S. C., Cantú, I., Banjanin, B., van Lom, K., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24574 · Cited by 8
“This depends on the particular combination of genomic variants carried by HPFH individuals [1].”
BackgroundInfluentialKey Pharmacogenomic Considerations for Sickle Cell Disease Patients
Κολλιοπούλου, Α., Στρατόπουλος, Α., Siamoglou, S., Sgourou, A., Ali, B. R., Papachatzopoulou, A., Κάτσιλα, Θ., & Patrinos, G. P. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0058 · Cited by 8
“Variants found at three principal loci ( HBS1L-MYB , BCL11A , and HBB clusters) make up for around 10% to 20% of interindividual variation regarding HbF levels (Creary et al., 2009; Menzel et al., 2007; Thein et al., 2009).”
Ayaz, M., Muzammal, M., Siraj, S., Fatima, S., Fatima, S., Khan, J., Khan, M. A., Shah, M. I., Rehman, Z. U., & Wei, L. (2023) · Expert Review of Hematology · doi:10.1080/17474086.2023.2241639 · Cited by 8
“These affected people have somewhat reduced lifetime [6,7].”
BackgroundTripathi, P., Agarwal, S., Mandal, K., Gupta, A., & Sarangi, A. N. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13010009 · Cited by 7
“Low levels of MYB are associated with reduced cell expansion and accelerated erythroid differentiation, suggesting that variation in the intrinsic levels of MYB might affect HbF by its effect on the cell cycle [6].”
BackgroundDurlak, M., Fugazza, C., Elangovan, S., Marini, M. G., Marongiu, M. F., Moi, P., Fraietta, I., Cappella, P., Barbarani, G., Font-Monclus, I., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141083 · Cited by 7
“Genome-wide association studies identified three major gene loci (Xmn1-HBG2, HBS1L-MYB and BCL11A) accounting for the majority of inherited HbF variance[10] but their exploitation as therapeutic targets is still distant.”
BackgroundDabke, P., Colah, R. B., Ghosh, K., & Nadkarni, A. H. (2012) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2012.11.003 · Cited by 7
“Several genetic loci are candidates for cis acting regulators of β globin gene transcription [13].”
BackgroundBeta-Globin Gene Cluster Haplotypes in Iranian Sickle Cell Patients: Relation to Some Hematologic
Galehdari, H., Pedram, M., Jaseb, K., Sh, B., Kh, Z., & Samadi, B. Y. (2012) · Iranian Journal of Blood and Cancer · Cited by 7
Maroofi, N., Azarkeivan, A., Banihashemi, S., Mohammadparast, S., Aghajanirefah, A., & Banan, M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0019 · Cited by 7
Inhibition of γ/β Globin Gene Switching in CD 34+ Derived Erythroid Cells by BCL11A RNA Silencing
Taghavi, S. A., Hosseini, K. M., Tamaddon, G., & Kasraian, L. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01131-8 · Cited by 7
Watanabe, A. M., Pianovski, M. A. D., Lenzi, L., & Cat, R. (2017) · Jornal Brasileiro de Patologia e Medicina Laboratorial · doi:10.5935/1676-2444.20170007 · Cited by 7
“Thein et al. (2009) suggested that the quantitative trait loci (QTL) XmnI-HB-G2, linked to the βS-globin gene, could be associated with severity of the disease, as well as genes not related to its cluster, such as HBS1L-MYB (6q23) and BCL11A (2p)(36, 37).”
BackgroundSankaran, V. G., Menne, J., & Heller, R. (2011) · Blood · doi:10.1182/blood-2010-11-320887 · Cited by 7
Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
Pandey, A., Estepp, J. H., Raja, R., Kang, G., & Ramkrishna, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051065 · Cited by 6
“The individuals wit HPFH condition express elevat d HbF levels in the rang of 10–40% [53].”
BackgroundPule, G. D., Bitoungui, V. J. N., Chemegni, B. C., Kengne, A. P., & Wonkam, A. (2016) · Hemoglobin · doi:10.1080/03630269.2016.1251453 · Cited by 6
Novel Therapy Approaches in β-Thalassemia Syndromes — A Role of Genetic Modifiers
Pavlović, S., Ugrin, M., & Stojiljković, M. (2015) · InTech eBooks · doi:10.5772/61023 · Cited by 6
“Genome-wide association studies indicate that variants in the HBB, HSB1L- MYB and BCL11A loci account for approximately 50% of the HbF level variation, suggesting that additional factors are involved [38, 39, 43, 57].”
BackgroundAnsari, S. H., Hussain, Z., Zohaib, M., Parveen, S., Kaleem, B., Qamar, H., Adil, O., Khan, M. T., & Shamsi, T. S. (2021) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000002136 · Cited by 6
Hemoglobinopathies and Thalassemia Syndromes
Perumbeti, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.07906-5 · Cited by 6
Donnelly, J. C., Cooley, S. M., Doyle, A., Murphy, D. J., Corcoran, D., Kumpel, B. M., & Áinle, F. N. (2013) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2013.10.012 · Cited by 6
“Residual low-level HbF continues to be synthesized during adult life [4].”
BackgroundHaji, H., Urio, F., Nkya, S. W., Chamba, C. C., Nasser, A., Lyimo, M. A., Ally, M., Mawalla, W. F., Jonathan, A., Kidenya, B. R., et al. (2025) · Journal of Blood Medicine · doi:10.2147/jbm.s493425 · Cited by 5
Bhagat, S., & Thakur, A. S. (2018) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-017-0729-3 · Cited by 5
Listì, F., Sclafani, S., Agrigento, V., Barone, R. M. E., Maggio, A., & D’Alcamo, E. (2018) · Hemoglobin · doi:10.1080/03630269.2018.1482832 · Cited by 5
Park, H., Bhatti, S. A., & Chakravorty, S. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27615 · Cited by 5
Proteomics Technologies and Applications
Abdurakhmonov, I. Y. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73445 · Cited by 5
Tepakhan, W., Kanjanaopas, S., & Srewaradachpisal, K. (2020) · Hemoglobin · doi:10.1080/03630269.2020.1811117 · Cited by 5
Ghazaiean, M., Darvishi‐Khezri, H., Najafi, B., Karami, H., & Kosaryan, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318751 · Cited by 4
Current therapeutic landscape of β-thalassemia: focus on gene therapy
Cheng, A. N., & Kwiatkowski, J. L. (2026) · Therapeutic Advances in Rare Disease · doi:10.1177/26330040261433028 · Cited by 4
Association between Different Polymorphic Markers and β-Thalassemia Intermedia in Central Iran
Sajadpour, Z., Amini‐Farsani, Z., Motovali-Bashi, M., Yadollahi, M., & Khosravi-Farsani, N. (2020) · Hemoglobin · doi:10.1080/03630269.2019.1709204 · Cited by 4
“RBCs and alleviating the disease symptoms [28,29].”
HBG2 and HBG1 Nucleotide Substitutions and Hbf Production in Thalassemia Patients
Curcio, C. (2019) · American Journal of Biomedical Science & Research · doi:10.34297/ajbsr.2019.04.000802 · Cited by 4
Al-Allawi, N. A. S., Atroshi, S. D., Sadullah, R. K., Eissa, A. A., Kriegshäuser, G., Al-Zebari, S., Qadir, S. M. A., Khalil, D., & Oberkanins, C. (2024) · Hemoglobin · doi:10.1080/03630269.2024.2319733 · Cited by 4
“Several genetic mechanisms have been linked to the TI phenotype, including the inheritance of mild β-thalassemia alleles, coinheritance of α-thalassemia, and the inheritance of polymorphisms associated with augmented hemoglobin F (HbF) production [2,3].”
BackgroundBuccheri, M. A., Spina, S., Ruberto, C., Lombardo, T., Labie, D., & Ragusa, A. (2013) · Hemoglobin · doi:10.3109/03630269.2013.800823 · Cited by 4
“Independent studies on different population groups confirmed the association between the T polymorphism and increased Hb F and fetal cells, with a milder condition among individuals with sickle cell anemia, β-thal or Swiss type hereditary persistence of fetal Hb (10,20).”
BackgroundResultInfluentialPule, G. D., Bitoungui, V. J. N., Chemegni, B. C., Kengne, A. P., & Wonkam, A. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2502-3 · Cited by 4
The Erythrocyte - A Unique Cell
Rajashekaraiah, V. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101007 · Cited by 4
Tripathi, P. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106748 · Cited by 4
The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment
Lai, M. I., & Ahmed, N. H. M. (2022) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x23666230123140926 · Cited by 4
Toma, S., Tenorio, M., Oakley, M., Thein, S. L., & Clark, B. E. (2013) · Hemoglobin · doi:10.3109/03630269.2013.848365 · Cited by 4
Self-citationDaniel, Y., Hill, K., Inusa, B. P. D., Thein, S. L., & Howard, J. (2011) · Hemoglobin · doi:10.3109/03630269.2011.592555 · Cited by 4
“We investigated whether the XmnI-HBG2 polymorphism, which is associated with increased levels of Hb F in adults and has a reported association with milder disease in sickle cell anemia (6) was involved in this phenotypic variation.”
BackgroundSelf-citationNovel Therapeutic Agents for HbF Induction: A New Era for Treatment of β Thalassemia?
Perrine, S. P. (2011) · Thalassemia Reports · doi:10.4081/thal.2011.s2.e7 · Cited by 4
Kountouris, P., Stephanou, C., Xenophontos, M., Minaidou, A., Christou, S., Savvidou, I., Rekleiti, A., Pyrovolaki, K., Konstantinou, N., Tshilolo, L. M., et al. (2026) · Blood Global Hematology · doi:10.1016/j.bglo.2026.100098 · Cited by 3
Brancaleoni, V., Moukhadder, H. M., Consonni, D., Koussa, S., Pierro, E. D., Cappellini, M. D., & Taher, A. T. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3567-3 · Cited by 3
miR-365-3p mediates BCL11A and SOX6 erythroid-specific coregulation: A new player in HbF activation
Simbula, M., Manchinu, M. F., Mingoia, M., Pala, M., Asunis, I., Caria, C. A., Perseu, L., Shah, M., Crossley, M., Moi, P., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.09.002 · Cited by 3
Recent perspectives of pediatric β-thalassaemias
An, Q., Fan, C., & Xu, S. (2018) · Minerva Pediatrics · doi:10.23736/s2724-5276.18.04872-7 · Cited by 3
Multi-Locus Models to Address Hb F Variability in Portuguese β-Thalassemia Carriers
Manco, L., Bento, C., Relvas, L., Cunha, E., Pereira, J., Moreira, V., Álvarez, M., Maia, T. M., & Ribeiro, M. L. (2020) · Hemoglobin · doi:10.1080/03630269.2020.1753766 · Cited by 3
“Moreover, a number of other SNP variants on these three major Hb F-influencing QTLs, were recognized in different populations worldwide in healthy individuals and in patients with hemoglobinopathies [27].”
BackgroundRedzuwan, Y. N. M., Assyuhada, M. G. S. N., Ghani, R. A., Za’ror, Y. S. M. A., Bahar, R., Azlan, M., Zulkafli, Z. B., & Saleh, R. M. (2021) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v20i3.52804 · Cited by 3
Thérapie génique pour la drépanocytose : avancées et obstacles
Cavazzana, M. (2023) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2023.06.015 · Cited by 3
Sudanese (δβ)0-Thalassemia: Identification and Characterization of a Novel 9.6 kb Deletion
Waye, J. S., Eng, B., Got, T., Hanna, M., Hohenadel, B.-A., Nakamura, L. N., & Walker, L. (2015) · Hemoglobin · doi:10.3109/03630269.2015.1057736 · Cited by 3
“It is likely that these differences are attributable to other genetic factors that govern the level of Hb F in adults (8,9).”
BackgroundReactivation of Fetal Hemoglobin in Thalassemia and Sickle Cell Disease
Eridani, S., Avemaria, F., & Mosca, A. (2014) · Thalassemia Reports · doi:10.4081/thal.2014.2196 · Cited by 4
Inherited Hemoglobin Disorders
Munshi, A. (2015) · InTech eBooks · doi:10.5772/59742 · Cited by 3
Consensus Predictive Model for Human K562 Cell Growth Inhibition through Enalos Cloud Platform
Afantitis, A., Leonis, G., Gambari, R., & Melagraki, G. (2017) · ChemMedChem · doi:10.1002/cmdc.201700675 · Cited by 3
Metadata
- Authors
- Thein, S. L., Menzel, S., Lathrop, M., & Garner, C.
- Affiliations
- King's College London (GB)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- University of California, Irvine (US)
- Corresponding author
- Thein, S. L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-06
- Volume
- 18
- Issue
- R2
- Pages
- R216-R223
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC2758709
- OpenAlex
- W2121678970
- Semantic Scholar
- 24f312a7a63abd9a348d7cd92da05ea68713d111
- Cited by
- 250
- References
- 64
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 10 · 2020: 15 · 2019: 15 · 2018: 10 · 2017: 24 · 2016: 16 · 2015: 19 · 2014: 19 · 2013: 15 · 2012: 16
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL069259, R01-HL69259-03)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- fetal hemoglobin, sickle cell disease, beta-thalassemia, hereditary persistence of fetal hemoglobin, quantitative trait loci, HBG2, HBS1L-MYB, BCL11A, beta-globin gene, HBB mutations, genome-wide association study, positional cloning, candidate genes, cell proliferation and differentiation
- MeSH terms
- Animals, Erythrocytes, Fetal Hemoglobin, Humans, Genetic Variation, Quantitative Trait, Heritable, Genomics, Quantitative Trait Loci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.